Xiaoli Qin, Ph.D. currently is Director of Research at Curegenix, Inc, an innovative therapeutic development company concentrating on novel anti-cancer therapeutic agents. She leads the biology program on drug development, focusing on companion diagnosis for clinical trials and testing. Dr. Qin has 10 years of experience in translating biomarker knowledge into clinical applications. Prior to joining Curegenix, Dr. Qin was Senior Scientist with increasing roles in clinical biomarker development and clinical virology at InterMune, Inc. Dr. Qin served on the Executive Council of Chinese American Biopharmaceutical Society (CABS), co-chairing the Business and Career Development Committee 2012-2014. She completed the graduate training at the Program in Innovation and Entrepreneurship at Stanford University School of Business targeted toward Silicon Valley innovators, scientists, and engineers working to gain greater understanding of the pathways to commercializing innovations and to learn general management skills. Dr. Qin received her B.S. degree from Peking University and her Ph.D. degree in Microbiology & Immunology through Stanford University School of Medicine. She conducted post-doctoral research in functional genomics and systems biology with Dr. Gerald M. Rubin at University of California, Berkeley.

Alan Hao, Ph.D. is a seasoned medicinal chemist with the passion of discovering innovative medicines to treat diseases with unmet need. He worked on various disease areas including cancer, inflammation, diabetes and obesity in Tularik and Amgen. During his industrial career over the past 15 years, Alan was responsible for providing scientific and technical leadership and strategic direction to the medicinal chemistry projects, and led the medicinal chemistry efforts to move three drug candidates into clinical trials. Most recently, Alan founded AIM Biosciences, with the goal of developing affordable innovative medicines for seriously ill patients. He received his PhD in organic chemistry from the University of Illinois at Chicago and BS from Peking University. He is the current president of CABS.

Guo-Liang Yu, Ph.D., is executive Chairman, Crown Bioscience Inc., an emerging biotech company with 400 employees dedicated to the development of personalized cancer therapeutics. Guo-Liang cofounded Epitomics, a leading monoclonal antibody company. Guo-Liang was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors by knock-out and over-expression in planta. Guo-Liang was a Senior Scientist at Human Genome Sciences Inc. where he discovered the target Blys for the lupus drug belimumab. Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University in Shanghai. Guo-Liang is a co-inventor of more than 200 patents and a co-author of 40 scientific articles. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and service on several professional organizations in the US and China as a member of the board of directors or board of advisory.

Bill Choy, Ph.D. MBA, ZC2 Consulting/pharmaceutical director. Bill got his BS in chemistry at UC-Berkeley, PhD in synthetic organic chemistry at UC-Santa Cruz, was a post-doc at MIT's chemistry department and got his MBA from Santa Clara University's executive MBA program. His industrial career (medicinal chemist and pre-clinical project manager) started in 1990 at Genelabs Technologies (now part of Glaxo Smith Kline since '09). He's a co-inventor of 5 US patents for drug discovery and

process development and co-authored 15 publications in peer reviewed journals. His current consulting career started in '00 as a retained consultant for Genovate Biotech (Taiwan's 1st biotech company) and focusses on selecting in-vitro/in-vivo protocols, designing clinical protocols and strategic marketing research. Among his recent clients are entrepreneurs starting-up drug discovery companies in China.'

Kenneth Fong, Ph.D., is the Chairman of Kenson Ventures, LLC. Kenson specializes in venture financing and strategic consulting to biotech companies. As of January 2003, Kenson has 18 investments that mostly fall into 3 major categories: a) Innovative Research Tools, b) Platform Technologies, and c) Drug Development. Prior to founding Kenson, Dr. Fong was the founder and CEO of CLONTECH Laboratories that was acquired by Becton Dickinson (BD) in late 1999. CLONTECH was the leader in the Molecular/Cell Biology market and in the last 4 years before its acquisition, the company had experienced an average growth rate of 36% a year. The company also had 48 consecutive quarters of double-digit growth and profits. In 1994, 1995, 1998, and 1999, CLONTECH was selected as one of the fastest-growing companies in the San Francisco Bay Area. Dr. Fong's past experience is best suited to young companies and to those that desire to grow more rapidly. He is also adept at crafting development strategy and realistic implementation plans to promote the long-term growth of a company. Under Dr. Fong's leadership, companies that either were acquired or went public between 2007 and 2010 are: SA Biosciences (to Qiagen); DHI (to Quidel); Fermentas (to ThermoFisher); Panomics (to Affymetrix); Bioform (IPO); and Optimer (IPO). Dr. Fong obtained his Ph.D. from Indiana University.

Tao Huang, Ph.D., J.D., Legal and IP Counsel, Cenova Ventures. Dr. Tao Huang has over 20 years of combined experience in biomedical research, legal, and business in academia and the life sciences industry. At Cenova, Dr. Huang oversees IP strategy for portfolio companies. Prior to Cenova, Dr. Huang was an attorney at several prestigious law firms in the US, including Wilson Sonsini Goodrich & Rosati and Morgan Lewis & Bockius. Dr. Huang has been advising companies and investors in the biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent counseling, licensing, litigation, VC financing, M&A, and IPO. Dr. Huang has provided legal representation to several notable business transactions, including Takeda’s licensing and collaboration deal with Alnylam relating to RNAi therapeutics (valued at $1 billion, with $100 million up-front fee), Ion Torrent’s acquisition by Life Technologies ($375 million), and QuantaLife’s acquisition by Bio-Rad Laboratories ($162million). Dr. Huang has also advised clients on high-stake litigation cases, including Brigham Young University v. Pfizer, Inc. (related to Celebrex, Pfizer paid $450 million to settle), and Life Technologies Corp. vs. Biosearch Technologies, Inc. (related to real-time PCR, settled). Dr. Huang received a B.S in Biophysics from Nankai University, a Ph.D. in Biochemistry from Peking Union Medical College/Chinese Academy of Medical Sciences, a J.D. from the University of Michigan Law School and his post-doctoral training in molecular biology and biochemistry from Princeton University. Dr. Huang is a registered United States Patent and Trademark Office attorney in the state of California.

Dr. Cheni Kwok is a Managing Partner and Founder of Linear Dreams LLC, a management consultancy and valuation software firm specialized in corporate strategy, business/corporate development, portfolio analysis, and valuation services for the life science industry. Prior to founding Linear Dreams LLC, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc.,

where she established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, Dr. Kwok was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics. Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society. Dr Kwok is currently serving as the co-chair of Business and Career Development Committee of Chinese-American BioPharmaceutical Society (CABS); Vice President of Chinese Bioscience Association (CBA); Marketing & Outreach Committee of CLP; Chair of California Chinese Unit (CCU) Leadership Council, Bay Area Regional Council Member and Health Equity Asian American and Pacific Islander Team Member of the American Cancer Society (ACS).

Charlene Liao, Ph.D., holds Ph.D. in Biology from Brandeis University and a B.S. in Biochemistry from Peking University. She conducted postdoctoral research in immunology and signal transduction at UCSF where she was a Fellow of the Damon Runyon Cancer Research Fund and a Special Fellow of the Leukemia and Lymphoma Society of America. Dr. Liao began her bio-pharmaceutical industry career at Tularik Inc. (now Amgen) as a Scientist. Prior to joining Genentech Dr. Liao held various leadership positions at Rigel Inc., including Project Leader, Associate Director, and Director of Business Development. Dr. Liao joined Genentech in 2002 and has been a Project Team Leader since 2007. She has contributed to IND filing for 8 NMEs including large and small molecule drugs and across the therapeutic areas of oncology, immunology and infectious diseases. Dr. Liao is one of the founding members and Board of Directors of the Ray Wu Memorial Fund, and a part of the "Executive Program for Women Leaders" at Stanford Graduate School of Business last year.

Shichang Miao, Ph.D., is the 2009-2010 president of CABS and a current member of its Board of Directors. He works as Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focused on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of Pharmaceutical & BioScience Society International (PBSS International; formerly CACO-PBSS), a scientific organization of 5000+ members with chapters in the San Francisco Bay Area, San Diego, Boston, Vancouver and Korea.

Janet (Jian) Xiao, Ph.D., J.D., is a partner in Morrison & Foerster's Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in

their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao has significant experience in developing and strengthening her clients' complex patent portfolios to maximize their commercial value and success. She advises biopharmaceutical companies such as Celgene and Genentech and research institutions such as University of California on patent matters relating to various technologies including antibody therapeutics, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from the inception. She also prepares legal opinions on patent validity and freedom to operate, conducts IP due diligence reviews for business transactions, and is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China. She is frequently called upon to advise clients on IP issues relating to US/China cross-border transactions and operations in China, and is frequently invited to speak on IP issues both in the US and in China.

Shelly Xiong, Ph.D., RAC is currently a director of Regulatory Affairs at InterMune, Inc. She has 20 years of pharmaceutical industrial experiences across a broad spectrum of drug development processes. She has extensive experiences in drug discovery, clinical development, regulatory strategy, and commercial activities. Prior to InterMune, she held various leadership positions at Gilead Sciences (regulatory affairs; principal scientist in clinical virology) and Covance (Director of China Operations). She was also a co-founder and Chief scientific Officer of a China-based start-up company. She received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.

Sean Wu, Ph.D., is a co-founder & Head of Discovery Services at Quintara Discovery, a drug discovery & development service company based in the San Francisco Bay Area. Sean has extensive experience in drug discovery. Prior to Quintara Discovery, he was Associate Director at Exelixis, leading a team of scientists for ADME profiling of all discovery and development compounds, including all the ADME support for Cometriq™. He is an editorial board member of Journal of Biomolecular Screening. Sean obtained his Ph.D. degree from Georgia Health Sciences University, and did post-doctoral research at Yale University and Novartis Pharmaceuticals.

Victor Lee, Ph.D. has spent his entire professional career in the life sciences. He started as a scientist in cancer research, and became an attorney specializing in intellectual property (IP) and technology transactions. His most recent position was VP & Chief IP Counsel at Celera Corporation, a publicly-traded company focused on molecular diagnostics and genetic testing. As part of Celera's executive team, he was involved in many strategic decisions of the company. The progression of his career allowed him to acquire new skills from the diverse experiences at every stage. These experiences have expanded his competencies and made him particularly effective in contributing to companies that rely on IP protection, because he understands both the mindset of a scientist working in a lab and the daily challenges of an executive operating a business, as well as the expectations outside investors. Over the past 20 years, he has helped universities, start-up ventures, public companies, and international corporations in building and commercializing their IP portfolios."

Dannis Chang, **Pharm.D** received his Bachelor of Arts degree in Molecular and Cellular Biology from UC Berkeley. After receiving his undergraduate degree, he worked in project management at

Genentech in the Translational and Molecular Oncology Division, as well as a researcher at LifeScan Inc. After a few years in the workforce, he returned to school and received a doctorate of pharmacy degree from University of Southern California and completed a 2 year post-doctoral PharmD Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division. During his time at Novartis, he rotated through various departments such as US and Global Medical Information Services, Field Medical Operations (MSLs), Managed Markets and Payer Access, and Scientific Communications. He also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Dannis joined Genentech Inc. in May 2012 as part of the U.S. Medical Affairs Department, where he currently serves as a senior product specialist for Avastin, with a focus in lung, renal cell, and gynecologic cancers. His experiences in the bio-pharmaceutical industry comprise multiple therapeutic areas including oncology, hematology, and immunology. In his spare time, Dannis enjoys volunteering at various shelters in the Bay Area, playing tennis, racketball and guitar, and cooking. He current resides in Burlingame, California.

Zhenhai Shen, Ph.D., MBA, is current Head for Research Services Procurement at Genentech/Roche responsible for research outsourcing activities for both Genentech and Roche. He received his Ph.D. Degree from The Mount Sinai School of Medicine and completed his postdoctoral training at Dana-Farber Cancer Institute. Zhenhai also holds a MBA degree from Ross School of Business of University of Michigan. Prior to Genentech, Zhenhai worked in Eli Lilly's International Finance group.

Gary Yeung, **MBA**, Head of gRED project management, Genentech/Roche, is a Senior Director of Portfolio Management and Operations at Genentech. He has 15 years of biotech and health care consulting experience. In his current role, he oversees the project management of Genentech drug development portfolio. His other leadership roles at Genentech include Portfolio Planning, Finance and Commercial Operations. Before Genentech, Gary advised health care clients at McKinsey, implemented corporate strategies at GE and raised capital and closed multiple partnerships at Cerus. Gary received his BS in Chemical Engineering from UC Berkeley, holds an MBA from UCLA and is a Chartered Finance Analyst (CFA) and certified Project Management Professional (PMP).

Darren Ji, Ph.D MBA, Vice President and Global
Head, Roche Pharma Partnering - Asia and Emerging Markets, Genentech/Roche.

Ying Gong, Ph.D., received her PhD in Biochemistry and Molecular Biophysics from Caltech, studying the molecular mechanisms of vertebrate morphogenesis using zebrafish as a model. Upon graduation, she joined the management consulting firm Bain & Company, where she worked on a broad range of business strategy and operations projects in different industries. Dr. Gong joined Genentech in late 2007, where she has been responsible for commercial strategies of R&D programs in a number of therapeutic areas. Recently, she moved to a new position within Genentech and is responsible for developing reimbursement strategies.

Zhengtian (Titan) Gu, Ph.D. is currently a Senior Director and head of Analytical Development and Quality Control at Theravance Biopharma, South San Francisco, CA. Titan has close to 20 years of research and development experience in the pharmaceutical industry. He received his college education at University of Science and Technology of China, and his Ph. D. in Biophysical Chemistry

from Columbia University in 1996, with postdoctoral fellowships at Memorial Sloan Kettering Cancer Center and University Pennsylvania, where he is a fellow of Leukemia Society of America. Since 1998, he has had various managerial and scientific positions at Theravance, 3M, GlaxoSmithKline and Procter & Gamble Pharmaceuticals. Dr. Gu has in depth experience in Chemistry, Manufacturing and Control (CMC) and preclinical development areas for IND and NDA filing at FDA. He made significant contributions to the successful approval of VibativTM in USA. He is the immediate past chair of Science Based Regulation Committee of ISPE.

Ruhong Jiang, Ph.D., is cofounder and CEO of Applied StemCell, Inc. located in San Francisco Bay area, chairman and CEO of Stanford Biotech, Inc. at China Medical City, Taizhou, Jiangsu Province in China. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx (Shanghai) Pharmaceutical, Inc. a California-based biopharmaceutical company where he set up its entire China operation. From 2005-2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then project manager at Genaissance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin's lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

Harry Liu, MD MPH MBA, has been working in the area of Drug Safety and Pharmacovigilance for the past 10 years. Most recently, he is Sr. Safety Scientist in Roche/Genentech responsible for an oncology molecule in late stage development. Previously, he worked in Amgen in the area of drug safety, pharmacovigilance, and pharmacoepidemiology. He also worked in clinical development in Johnson & Johnson, and conducted medical research in UCSF. He has a medical degree from Jilin University, a MPH from UC Berkeley, and a MBA from UCLA.

Jiwen (Jim) Liu, **Ph.D.**, worked at Amgen for 16 years for small molecule drug discovery. He served as a project leader for a number of programs over several therapeutic areas, and contributed to five molecules tested in clinical trials. His accomplishment benefited from his tireless effort, insatiable curiosity, open mindedness, and teamwork spirit. He has recently left Amgen, and is working on two startup companies. One in biotech, and one in IT. Given the odds against the success of startups, he strongly believe his companies will be successful. He does not believe a set formula for any career. He believes a good career comes from a good life. He does not think he will have answers to many

questions of his mentees, but wants to work together with them to learn and grow. He will share his experiences and knowledge, but more importantly, he wants to encourage his mentees to look and identify their unique career paths.

Youling Zou, MS, MBA., Program/Product Manager at Baidu US. Youling currently works as a Program Manager at Baidu US office. She set up and oversaw the business operation of Baidu US office in Sunnyvale, and is working as a Product Manager. Before joining Baidu, Youling worked in a venture capital firm (GSR Ventures) and a biotech company (Epitomics). Youling had a MS in biochemistry and obtained her MBA from UC Berkeley, Haas School of Business. She did her MBA intern focusing on Global Product Strategy (Oncology) in Genentech.

Taotao Chen, Ph.D., has been a Scientific Manager and Group Leader at Lakepharma Inc since Jan. 2015. Dr. Chen holds Ph.D. in Biochemistry from Ludwig Maximilian University of Munich and Max-Planck Institute of Biochemistry, Germany and M.S. from Chinese Academy of Sciences, Beijing, China. In 2012, he joined in labs of Judith Frydman at Stanford and Raul Andino at UCSF as a postdoctoral research fellow. He founded the Department of Postdoctoral Scholars in the Association of Chinese Scholars/Students at Stanford and CampusDrive LLC in 2014.

Bo Lian, Ph.D., currently working at ONYX/Amgen as a scientist in Pharm Sci, responsible for formulation development and process optimization for oral and injectable medicine. Bo has a PhD in Pharmaceutical Sciences. After finishing his P.hD. Bo joined ONYX.

Lingjie Guan, Ph.D. currently working at Bayer as Senior Quality Assurance Specialist Commerical Operations, responsible for biologics product quality lifecycle management. Before that she worked at Qiagen as lead bioinformatics training scientist. Lingjie has a PhD in molecular biology. Prior to joining the workforce, Lingjie spent one year in postdoctoral research in UCSF.

Vincent Xiang, Ph.D MBA, Managing Director of International Investments and Business Development of Humanwell Healthcare Group. Dr. Xiang obtained his Ph. D degree in molecular biology from SBU and later MBA degree from Wharton. In 2013, Dr. Xiang's research CPR15-mediated homing control immune homeostasis in the large intestine mucosa was published on Science. Dr. Xiang has over 20 years of experience in biopharma industry and has invested global life science firms at all stages. He had served as managing director of Burrill & Company and later as vice president in Franklin Templeton Inv, co-managing the Franklin Biotech Discovery Fund. Dr. Xiang is also an active participant in promoting industry communications between China and US, being the founding member of BayHelix Group and member of CABS and SAPA.

Aihua Fu, Ph.D. is a co-Founder and CEO of NVIGEN Inc., a nanobiotech focusing on magnetic and fluorescent magnetic nanoparticles enabled sample and assay technology. Dr. Fu has over 12 years' experience in developing nanoparticles for biomedical applications. She holds a Ph.D. degree in Chemistry from University of California at Berkeley in the research group of Dr. A. Paul Alivisatos. She has a M.S. degree from Rutgers University and a B.S. degree from Beijing University of Chemical Technology. Her postdoctoral research at Stanford University was supervised by Prof. Shan X. Wang and Prof. Sam S. Gambhir to engineer nanoparticles with enhanced properties for in vitro diagnostics

and in vivo cancer imaging and drug delivery applications. She has won many awards and honors including Dow Chemical Award, Du Pont Award, the Materials Research Society Graduate Student Award, the Obducat Prize and the NIH Pathway to Independence Award.

Qiang Chen, Ph.D. currently is Quality Product Leader at Genentech, Inc., a member of Roche Group. He serves as the end-to-end quality oversight of several small molecule clinical development projects. Dr. Chen has 18 years of industrial experience in the areas of pharmaceutical development, medical device, combination products for both traditional dosage forms and innovative delivery technology. Prior to joining Genentech, Inc., Dr. Chen served for several companies in Bay Area mainly in Quality and Analytical Sciences. Dr. Chen was Director of Analytical Development at Allergan (2012-2013), Senior Director of Quality Control at Alexza Pharmaceuticals, Inc. (2004-2011), Senior Scientist at Corium International (2002-2004), Sr. Manager of Analytical Sciences at Cygnus Inc. (1997-2002). Dr. Chen also served as President of United Chinese University Association in 2013, and has served as President of Xiamen University Alumni Association in Silicon Valley since 2010. Dr. Chen completed his undergraduate and graduate from Xiamen University and taught analytical chemistry for 6 years at Xiamen University before coming to the US pursuing his PhD degree. Dr. Chen received his PhD degree from New Mexico State University in 1995. He then conducted post-doctoral research in biosensor development with Dr. Adam Heller at University of Texas at Austin between 1995 and 1997.

Zhengping Wang, Ph.D. is currently Director of Drug Metabolism and Pharmacokinetics (DMPK) at Onyx Pharmaceuticals, A Subsidiary of Amgen. Her team is responsible for providing Drug Metabolism, Pharmacokinetics and Bioanalytical support for discovery and development programs at Onyx. She was a key member in the development of Kyprolis, a new generation proteasome inhibitor for the treatment of multiple myeloma. Prior to Onyx, Dr. Wang was Senior Scientist at Proteolix Inc. from 2007-2009. She started her industry career in 2002 at Cytokinetics Inc., where she transitioned from proteomics to DMPK and held roles with increasing responsibilities. Dr. Wang obtained her Ph. D. in Analytical Chemistry from the University of Alberta, Canana. She is a member of America Association of Pharmaceutical Scientists (AAPS), American College of Clinical Pharmacology (ACCP) and The American Society for Pharmacology and Experimental Therapeutics (ASPET).

Hangjun Zhan, Ph.D., is a well-established protein biochemist and biophysicist with 20 years of drug discovery experience in the biotechnology industry. He is currently as vice president at KindredBio to lead their biologics research. Previously, Dr. Zhan served as an Executive Member at Aragen Biosciences and led their protein sciences efforts. He played a key role in transforming the organization into one of the most comprehensive biologics services in the CRO business. Prior to serving at Aragen Biosciences, Dr. Zhan had joined Exelixis, Inc. in 2000 to establish their Protein Biochemistry Group. As Senior Director, he successfully managed multiple groups, including Protein Expression, Fermentation/Bioproduction, Protein Purification/Biophysics, and Proteomics. His team contributed directly to Exelixis' drug discovery programs, leading to more than 20 drugs at various phases of clinical trials and FDA-approved drug. Dr. Zhan was Group Leader of Protein Chemistry at Axys Biopharmaceuticals (Celera), where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier's lab at Harvard Medical School, where he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. He received his Ph.D. from the University of Washington, where he

discovered a novel chemical signaling molecule involved in bacterial invasion.

Frank Shugui Huang, Ph.D., President & CEO, BioAssay Systems. Dr. Huang got his BS in organic chemistry from Sichuan University (1985), MS in analytical chemistry from Chinese Academy of Sciences Chengdu (1988). He received his Ph.D. biochemistry from the University of Munich in 1994. From 1994 to 1998 he was assistant professor at the University of Munich. Dr. Huang joined Tularik, Inc in 1998 working as a drug discovery scientist. From 2002 to 2005 he was director of drug discovery at AGY Therapeutics, Inc. Thereafter Dr. Huang started his own biotech company, which specializes in assay development, manufacturing and selling assay products to serve the life sciences industry.

Kedan Lin, Ph.D. is a Senior Scientist and Therapeutic Area Leader for Oncology Large Molecules in the Department of Pharmacokinetics & Pharmacodynamics at Genentech. She has fifteen years of discovery and development experience in both small molecules and biologics. Her group is responsible for characterizing PKPD properties for oncology large molecules and applying integrated quantitative pharmacological approach in selecting and optimizing novel therapeutics. She also leads multiple pharmacology teams for antibody drug conjugates, and her teams are responsible for overall pharmacology support from discovery to clinical development. Prior to Genentech, she held positions of increasing responsibilities at Celera Genomics and Exelixis. Kedan received her Ph.D. from University of California, San Francisco.

Wentao Zhang, Ph. D., is Founder of Quintara Discovery, a biotech company focusing on drug discovery and development services that include in vitro ADME, bioanalysis and assay development in South San Francisco. Previously, Dr. Zhang was Senior Director of Lead Discovery at Exelixis from 2001 to 2012, managing key drug discovery platform and functions that include compound library management, assay development and high-throughput screen efforts, lead optimization, ADME operations and HERG safety pharmacology. Dr. Zhang has worked extensively in targeted drug discovery covering kinases, GPCR's and nuclear hormone receptors using a wide spectrum of enabling technologies. The drug discovery technology platform that Dr. Zhang helped to establish has generated and progressed over 20 compounds from discovery to clinical development, including candidates in phase 2 and 3 clinical trials, and Cometriq™, a novel kinase inhibitor approved for medullary thyroid cancer by the FDA in 2012. Before that, Dr. Zhang was a Staff Scientist at Genelabs Technologies from 1999 to 2001 responsible for biochemical and biophysical assays in the therapeutic areas of oncology and infectious diseases. In 1997-1999, Dr. Zhang was a postdoctoral fellow at University of California-Berkeley. He obtained his Ph.D. from University of Wisconsin-Madison, M.S. from Emory University and B.S. from Peking University. Dr. Zhang has published extensively in peer-reviewed scientific journals and holds multiple patents. He has been actively involved in various professional services and organizations, including serving on the NIH study section on assay development. Dr. Zhang has extensive management experience and has played key leadership roles in various biopharmaceutical companies. Dr. Zhang was President of the Chinese-American Biopharmaceutical Society (CABS) in 2012-13.

Shih-Chen Chang, PhD, 2015 CBA **President** Shih-Chen currently worked in Genentech as a senior Real World Data Scientist supporting infectious disease (ID) area since September 2011. Before he joined in the company, he worked at AstraZeneca for ~5 years in global epidemiology department,

covering oncology and ID therapeutic areas, and spent 3.5 years for his post-doctorate training on cancer epidemiology at National Cancer Institute. He obtained his PhD in School of Public Health, Johns Hopkins, and Master of Science and Undergraduate degree from National Taiwan University. Soon after his move to SF Bay area, Shih-Chen participated in his first 2011 CBA annual meeting and joined the CBA Committee board in 2012, supporting publication and sponsorship. He subsequently took the role as vice president in 2013 and chaired the annual conference. Shih-Chen has great passion to serve the community. Looking forward he hopes to continue building the foundation for the growing CBA, and promote this exciting organization to the greater Bay area bioscience communities.